News

Phase 1b dose escalation stage of the Phase 1b/2 Zantrene study in AML has completed using a 4-day treatment of Zantrene in combination with fludarabine and clofarabineEncouraging clinical responses were…

Race Oncology Limited (“Race”) is pleased to announce it has received Research Governance Office (RGO) approval from the Calvary Mater Newcastle Hospital for its open label clinical trial of Zantrene®…

March-2022-Quarterly-Activity-Report-and-Appendix-4CDownload

Race Oncology CSO Dr Daniel Tillett talks to WIN Television News about Race Oncology's research collaboration with the University of Wollongong.

6 April 2022 – Race Oncology Limited (“Race”) is pleased to announce it has receivedhuman ethics approval for its open label clinical trial of Zantrene® (bisantrenedihydrochloride) in patients with extramedullary…